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1. Introduction 
Non-melanoma skin cancer (NMSC) is the most common form of malignancy.  The annual 
incidence of NMSC had previously been estimated to be over one million cases per year in 
United States.(1) A recent study has shown that estimated burden of NMSC to have 
increased approximately to 3.5 million annual cases, affecting over 2 million people. (2,3) 
Although the burden of NMSC measured in terms of mortality and morbidity is thought to 
be relatively modest, the direct costs of NMSC are substantial owing to its high incidence.  
In the US Medicare population, it is considered a major health care problem and among the 
five most costly cancers to treat based on the actual economics of this disease. (4,5) In fact the 
estimated treatment costs of NMSC exceeded $500 million/year a decade ago.(6) More 
common than all other cancers combined, NMSC has been associated metachronously with 
the development of other malignancies. (7,8)   
In general, due to an underappreciation of its increasing prevalence and potential to be 
highly aggressive, NMSC has been relatively overlooked.  While the molecular profiles of 
melanoma have been well characterized given its stature as the most lethal type of skin 
cancer, those for NMSC have lagged behind.  In this chapter we discuss the numerous types 
of NMSC, their biologic variability and the various risk factors and etiologies.  The etiologies 
for the subset of NMSC with the most mortality, cutaneous squamous cell carcinoma (cSCC) 
will be summarized. Despite the fact that the majority of these tumors present at early 
stages, cSCC accounts for the majority of NMSC deaths and 20% of all skin cancer- related 
deaths. (9,10) We will review the clinical approach and scientific methodologies that are used 
to analyze skin biopsies specifically evaluating differential gene transcription between 
patients who either have a definite propensity to develop cSCC or vary in their 
susceptibility to developing cSCC.  In summary we will introduce where the field stands in 
the discovery of a molecular profile.   
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As the most frequent cancer in the US and worldwide, NMSC has been increasing in overall 
incidence since the 1960’s at a rate of 3-8% per year.(11, 12) With over 3.5 million new 
diagnoses of NMSC per year in the United States, it is both the diversity of types, of which 
there are 82, and biologic variability in phenotype, that makes the analysis of NMSC even 
more challenging.(2)   
Although the incidence of basal cell carcinoma (BCC) exceeds cSCC by a 5:1 ratio, cSCC is 
associated with the burden of mortality with a yearly disease-specific mortality rate of 1% 
per year as reported in the early 1990’s.(13) Despite the fact that the majority of these tumors 
present at an early stage, cSCC accounts for the majority of NMSC deaths and 20% of all 
skin cancer- related deaths.( 9,10) Recurrent NMSC carries a very poor prognosis with only a 
50% cure rate.(14) In contrast malignant melanoma is the deadliest at 60% of skin cancer 
deaths, which explains the primary focus on melanoma, albeit it is the rarest skin cancer at 
1% of skin malignancies.(15) 
Most suspicious skin lesions are more often evaluated by a primary care physician than a 
dermatologist, but both face the need to identify if a lesion is malignant, premalignant or 
benign.  To appreciate the breadth of the differential diagnosis, a study of 1215 biopsies 
from a primary care population were evaluated and 80% were benign lesions, 7% 
premalignant lesions, including actinic keratoses and lentigo maligna, with 13% being 
malignant.  The malignancies included 73% BCC, 14% SCC, and 12% malignant 
melanoma.(16) There are multiple precursor skin lesions for NMSC and include Bowen’s 
disease, SCC in situ (erythroplasia of Queyrat), and actinic keratoses.    
2. Paradigm shift in staging guidelines 
In light of the large number of low risk lesions with a cure rate of greater than 90% for the 
routine lesion, the significance of an increasing incidence of cSCC is not fully recognized, 
given the often quoted 5-year recurrence and metastatic rates of 8% and 5%, 
respectively.(10,17,18) With the diverse spectrum of lesions, clearly grouping the worst subset 
in with the high incidence of low grade lesions numerically minimizes the poor outcomes 
associated with the most aggressive lesions. In January 2010, the 7th Edition of the American 
Joint Committee on Cancer (AJCC) Staging Manual introduced a dramatic paradigm shift in 
the staging of cSCC to better incorporate known clinical predictors of poor outcome into the 
classification system and thus better group the diversity of lesions properly.  It is this edition 
that has launched a better rationale to track lesions based on their aggressive characteristics 
and to more comprehensively stage lesions.   
The recent changes to the AJCC Staging Manual focus on identifying clinical parameters 
that portend a worse prognosis to identify and stage appropriately that subset of cSCC 
that progresses to metastatic disease.(19) These factors include lesional size (> 2cm), and 
high risk features including a depth of invasion (>2mm, ≥Clark level IV), perineural 
invasion, tumor grade (poorly differentiated or un-differentiated), as well as high-risk 
anatomic sites (See Table 1).  Tumor grade alone is significantly associated with mortality 
given a 5-year cure post therapy of 61.5% for poorly differentiated cSCC compared to 
94.6% for well differentiated.(10) High risk histologic features were defined as showing 
poor differentiation, spindle cell characteristics, necrosis, high mitotic activity and deep 
invasion.19  Both the depth of invasion and presence of perineural invasion significantly 
correlate with prognosis and >4mm thickness or depth of invasion of ≥Clark level IV are 
associated with a 2 fold increased rate of recurrence or 5-fold increase metastatic rate; 
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similarly, perineural invasion is associated with a 5-fold increase in both the recurrence 
rate and metastatic rate.(10,20)  Although not identified in the 7th Edition of AJCC, other 
histologic features are important in prognosis and those include lymphovascular invasion 
and the presence of inflammatory features such as the presence of eosinophils and plasma 
cells.(21)  cSCC in immunocompromised patients or those that arise in scars, sinus tracts or 
burns all demonstrate a more aggressive biologic phenotype with a greater metastatic rate 
of up to 40%.(10,22,24)  So not only are subsets with a worse prognosis critical to correctly 
stage in order to appropriately recognize an unrecognized metastatic potential,  but also 
recurrent disease or persistent disease both portent a worse survival of 78% 5-year 
survival.(20,25) 
 
 
Histologic Differentiation
Poor differentiation
Spindle cell characteristics
Necrosis
High Mitotic Activity
Deep Invasion
Depth of Invasion
>2mm
Clark Level ³IV
Perineural Invasion
High Risk Anatomic Sites
Nonglabrous Lip
Ear
Advanced T stage (T3 and T4)
Bony extension or involvement 
Maxilla, mandible, orbit, temporal bone 
Perineural invasion
Invasion of Skull base
Invasion of axial or appendicular skeleton
 
Table 1. High Risk Factors For NMSC Tumor Characteristics* 
                                                 
* 7th Edition of American Joint Commission on Cancer Staging Manual (19) 
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3. Overview of treatment  
Standard surgical excision remains the mainstay of treatment of NMSC. The traditional 
surgical methods include excisional biopsy with appropriate margins or MOHS surgery for 
areas in which margins are limited by anatomy.   These so called critical areas include the 
commissure of the lip, nasal ala or canthus of the eye as shown in Figure 1.   Mohs surgery is 
a microscopically controlled procedure allowing for the narrowest surgical margin (1mm-
1.5mm).  Ideally, the Mohs resection should include 100% of the epidermal margin, but 
often 95% is conventional or at least 70% is accepted for frozen section analysis.(26) A 
conservative approach such as serial sectioning, proper staining technique, and a 
conservative Mohs margin (~at least 200 micrometer from the surgical margin) can assure 
the lowest recurrence rate. The use of frozen sections for margin control increases the cure 
rate of conventional surgical excision to be comparable with Mohs excisions. 
 
 
Fig. 1. Clinical presentations of Non-melanoma Skin cancer cutaneous squamous. Cell 
carcinoma (A and D) Basal Cell Carcinoma (B and C). Courtesy from Skin Cancer Guide CA. 
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Larger lesions should be biopsied with an incisional technique.  A scalpel or a 2 or 3 mm. 
dermatologic punch can be used.  The biopsy should avoid any area that appears to contain 
necrotic tissue.  It is often best to biopsy at the apparent margin of the malignant lesion with 
normal skin.  The biopsy should be “full thickness”, including epidermis, dermis and 
subcutaneous tissue.  This will allow adequate evaluation of the depth of invasion and allow 
for surgical planning.  Small lesions can be excised with a 0.5 to 1 cm. margin.  Larger 
lesions will require a 1cm. or wider margin  
Traditional histology of skin tissue uses vertical sectioning with the subcutaneous  
tissue at the bottom and the epidermis at the top. In contrast, Mohs surgery uses 
tangential or horizontal sectioning.  Thus the samples from biopsies are typically 
formalin-fixed paraffin-embedded tissue blocks or frozen tissue specimens from Mohs 
surgery.  These tissue specimens are first analysed for histologic review or evaluated by 
Mohs mapping.  The mapping combined with the unique "smashing the pie pan"  
method of processing such that the corollary of the blood covered surgical margin is an 
aluminum pie pan.  The top of the pie is the crust covered surface of the skin and the goal 
is to flatten this specimen into one flat sheet, mark it, stain it, and examine it under the 
microscope.(27) 
Notably there are many nonsurgical modalities, including cryosurgery, electrodessication 
and curettage, radiotherapy and intralesional therapies.  However, all these later approaches 
lose the benefit of pathologic analysis.  Thus it is easy to understand why capturing the 
actual incidence of NMSC has been difficult.  In the era of personalized medicine, molecular 
markers have been used in many tumors to prognosticate and risk stratify patients.  Given 
the relative lack of recognition of the growing incidence of cSCC  and the inability to track 
the worst subset of cSCC given the abundance of low risk lesions and the practice of not 
banking or staging lesions, these molecular studies have been relatively limited compared to 
the field of melanoma. 
4. Risk factors 
Multiple etiologies exist for cSCC, including environmental, genetic, altered immunity and 
virally mediated.  The high incidence of cSCC and BCC is primarily attributed to sun 
exposure and the mutagenic effects of ultraviolet (UV) light worsened by geographic 
latitude.(11,28) Cutaneous SCC and BCC are more common in fair skinned patients and 
anatomic sites exposed to the sun, such as head, neck and extremities: head and neck is the 
most common site. Other known risk factors are male sex, advanced age, 
immunosuppression (induced or acquired), human papilloma viruses (HPV), chronic 
inflammation and genetic diseases manifested in the skin.(28-30) Genetically inherited skin 
conditions that have a known propensity of risk for developing cSCC are albinism, 
xeroderma pigmentosum, and epidermodysplasia verruciformis.(9,31-32) The strongest risk 
factors for NMSC mirror the etiologies and include Caucasian race, older age 55-75 years of 
age, male sex, a prior diagnosis of NMSC confers a 10-fold risk for recurrence, and 
immunosuppression, as well as genetic, chemical and environmental factors (See Table 2).  
Likewise sites of chronic inflammation, such as scars, sinus tracts, and burns, can also 
demonstrate more aggressive clinical behavior and a greater propensity to metastasize with 
an overall metastatic rate of 40%.(10,22)   
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Significant Risk Factors
Caucasian
Immunosuppression
Previous NMSC or precursor lesion
Age 55-75
Male sex
Genetic Risk Factors
Blue eyes
Fair skin
Celtic ancestry
Genetic Syndromes
Xeroderma Pigmentosum
Albinism
Epidermodysplasia verruciformis
Basal cell nevus syndrome
Chemical Exposure
Coal Tar
Tobacco
Environmental Exposure
Ionizing radiation
Primary Inflammatory skin disorder
Chronic wounds, burns, scars
 
Table 2. Potential Risk Factors for NMSC 
5. Immunologic altered host state 
Several studies have demonstrated an association between an enhanced risk of NMSC and 
immunosuppression in patients with inflammatory bowel disease (IBD), rheumatoid 
arthritis (RA) and solid-organ transplants.(33- 35)  Malignant lesions develop within 10 years 
after organ transplantation.  The prevalence of NMSC in renal transplant recipients (RTR) is 
5% and from 10% to 27% at 2 and 10 years, respectively, but increases up to 40% to 60% at 20 
years.(36) In the long-term follow-up, this represents an increase of 12 to 90 times the NMSC-
risk in the general population.(35) Similarly, in heart transplant recipients, the cumulative 
risk rose from 4.3% at 1 year up to 43.8% at 7 years after transplantation.(37,38)  
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More importantly, the incidence and risk of malignancy particularly cSCC is significantly 
elevated in post-transplant patients compared to other patient populations.  
Immunosuppression is associated with a disproportionate increase in the incidence of cSCC 
of up to 64-250 times greater than that in the general population compared to the 10-fold 
increased risk in BCC.  This disproportionate increase causes a reversal of the expected 
5:1ratio of BCC: cSCC in immunocompetent individuals to a range between 1:1.8 and 1:15 in 
those that are immunosuppressed.(39,40)   
Furthermore, immunosuppression significantly impacts the biology and aggressiveness of 
cSCC.  In solid organ transplant patients, cSCC tumors tend to be numerous, exhibit a 
strong propensity to recur and metastasize at a high rate regardless of lesional size.(41) Skin 
malignancies in transplant recipients has some features that differ from those in the general 
population; (i) multiple sites are involved, (ii) the cancers occur in younger age-group (30 
years vs. 60 years), (iii) the cancers are more aggressive and recur more frequently, and (iv) 
the squamous cell type is more common than basal cell.(42) 
6. Viral pathogenesis 
The increased incidence of cSCC in immunocompromised patients compared to BCC 
suggests a mechanism of viral pathogenesis.  Evidence of HPV has been reported in cSCC in 
organ transplant patients with up to 80% of lesions containing HPV DNA as well as the 
presence of a higher viral load of HPV DNA.(43,44) However the variable quantity of HPV in 
immunocompetent individuals can range between 27-70% depending on detection 
techniques.(32,44) Thus the type of HPV, β-papillomavirus species 2, may be more often 
associated with cSCC as opposed to the total amount of HPV DNA present.32   
Three theories have been suggested for the mechanism of HPV carcinogenesis: 1) UV 
radiation induced immunosuppression to explain an enhanced interaction between HPV 
and UV radiation, 2) E6/E7 oncoprotein-related changes in p53 and Rb tumor suppressor 
gene, and 3) integration of HPV DNA disrupting genomic stability.(32,45,46). Viral expression 
of E6 and E7 oncoproteins can inactivate p53 and Rb tumor suppessor genes, leading to an 
uncontrolled system of cell proliferation and apoptosis.(47) 
Association of viral pathogens such as human papillomavirus (HPV) with head and neck 
squamous cell cancer (HNSCC), especially oropharyngeal cancer has been recognized over 
the past two decades. HPV16 is the most common genotype in these tumours, whereas 
HPV6 and HPV11 can also be found in a minority of these cancers, implying that these low-
risk HPV types are not entirely benign in HNSCC. HPV DNA is closely associated with 
poorly differentiated cancers, positive lymph nodes and late-stage disease, which portend a 
worse diagnosis.  HPV status is also associated with p16 expression and HPV+ tumours are 
less likely to harbour p53 mutations.(48) A subset of HNSCC patients who had HPV 16 
infection confers a better prognosis.  On the other hand, β papillomaviruses (β- HPVs) also 
play a role in the tumorigenesis of cSCC as shown by both European and US studies.(49) 
However, no high-risk types have been identified although there is an association of β 
species 1 in SCC.  Other viruses, such as polyomavirus (MCPyV) have been shown to be 
causative agent in Merkel cell carcinoma.(50) 
7. Allelic imbalance and loss of heterozygosity 
The genetic progression model for head and neck squamous cell carcinoma (HNSCC) 
demonstrates that loss of heterozygosity (LOH) is common during the progression from 
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premalignant lesion to malignant tumors.(51) Tumor suppressor genes (TSGs) are usually 
found in the area of loss rendering the cells more susceptible to tumorigenesis.(52) 
Several regions of chromosomal loss are identified in HNSCC.  One of the most common 
regions, 9p21, has been reported in both HNSCC and cSCC.(53,54)  This region contains 
several TSGs, including p16INK4A (CDKN2A), p15INK4B and MTAP.  Allelic imbalances 
are also found in other regions of cSCC, including LOH on 3p, 2q, 8p, and 13 and allelic gain 
on 3q and 8q.(55) Such studies indicate that allelic imbalance and LOH are recognized and 
relevant events in cSCC and can be used for early diagnosis and tumor surveillance. 
8. Epigenetics 
Epigenetics is the inheritance of genetic information that is altered in gene expression 
without changes in the DNA sequence.  Epigenetic alterations include DNA methylation 
and histone modifications, which consist of methylation, acetylation, phosphorylation, 
ubiquitination, and sumoylation. Changes in genomic DNA methylation associated with 
cancer include global DNA hypomethylation and gene-specific hyper- or hypomethylation.  
All of these modifications of gene expression have been associated with the development of 
various tumor types, including HNSCC and cSCC.(56,57) A higher frequency of FOXE1 
promoter hypermethylation has been documented in SCCs (55%) which was seen in 
association with a complete absence of or downregulated gene expression, indicating that 
FOXE1 is a crucial player in development of cutaneous SCC.(56) 
Promoter DNA methylation gene panels have been described for screening of primary 
HNSCC, for determination of tumor recurrence, and assessment of margin status during 
surgery.(58,59) However, a determination of methylation gene panels relevant in cSCC is yet 
to be established.  A combination of different genes from different pathways may allow for a 
better determination of the aggressiveness of cSCC to determine prognosis. 
9. RNA and MiRNA 
Messenger RNA (mRNA) and microRNA (MiRNA) profiles have been described in both 
HNSCC and cSCC.(60) MiRNAs play a role in regulation of mRNA. Several mRNA 
biomarkers for cSCC were identified, including CCR10, CCL27, MUC4, p16, MMP2 and 
MMP9.(61) A recent study has demonstrated that a distinct microRNA profile is modulated 
by UV radiation.(62)   
10. Mitochondrial mutation 
Mitochondrial mutation in HNSCC has been well reported; however, only a few studies 
show the association of mitochondrial DNA mutation and cSCC.(63) Several regions of 
mitochondrial DNA were reported, including displacement-loop (D-loop) and other 
regions.(64,65) Therefore, mitochondrial mutations may correlate in the future with the 
phenotypic behavior of cSCC. 
11. Conclusions 
The molecular mechanisms that underlie the development of cutaneous skin cancers are 
poorly understood. Even the spectrum of biologic behavior has been slow to be 
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characterized given the previously very generic clinical criteria used to distinguish low risk 
lesions from more aggressive lesions.   Recent changes in the classification of the staging 
paradigm have better captured this more aggressive subset to allow for a more precision in 
identifying the worst subset.  Thus molecular analysis can potentially profile that subset 
with biomarkers chosen to best correlate with the biologic phenotype. 
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